Kidney disease and mortality in patients with respiratory tract infections: a systematic review and meta-analysis. by Su, Guobin et al.
O R I G I N A L A R T I C L E
Kidney disease and mortality in patients with
respiratory tract infections: a systematic review and
meta-analysis
Guobin Su 1,2,3,4,*, Masao Iwagami5,6,*, Xindong Qin2, Helen McDonald5,
Xusheng Liu2, Juan Jesus Carrero4, Cecilia Stålsby Lundborg3 and
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ABSTRACT
Background. Respiratory tract infections (RTIs) are a common reason for people to seek medical care. RTIs are associated
with high short-term mortality. Inconsistent evidence exists in the association between the presence of kidney disease and
the risk of death in patient with RTIs.
Methods. We searched the PubMed, Cochrane Library and Embase databases from inception through April 2019 for cohort
and case–control studies investigating the presence of kidney disease (defined as medical diagnosis of kidney disease,
reduced estimated glomerular filtration rate or creatinine clearance, elevated serum creatinine and proteinuria) on
mortality in adults with RTIs in different settings including community, inpatient and intensive care units. We assessed the
quality of the included studies using Cochrane Collaboration’s tool and conducted a meta-analysis on the relative risk (RR)
of death.
Results. Of 5362 records identified, 18 studies involving 16 676 participants met the inclusion criteria, with 15 studies
investigating pneumonia and 3 studies exploring influenza. The risk of bias in the available evidence was moderate. Most
[17/18 (94.5%)] of studies reported positive associations of underlying chronic kidney disease with mortality. The pooled
adjusted risk for all-cause mortality in patients with RTIs almost doubled [RR 1.96 (95% confidence interval 1.48–2.59)] in
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patients with kidney disease. Associations were consistent across different timings of kidney disease assessment and
provenances of RTIs (community-acquired or healthcare-associated).
Conclusions. The presence of kidney disease is associated with higher mortality among people with RTIs, especially in
those with pneumonia. The presence of kidney disease might be taken into account when considering admission for
patients who present with RTIs.
Keywords: chronic kidney disease, influenza, meta-analysis, mortality, pneumonia, respiratory tract infection
INTRODUCTION
Respiratory tract infections (RTIs), including pneumonia and in-
fluenza, are common and can be life-threatening if not treated
promptly [1]. With >290 million episodes each year globally,
RTIs are among the most common reasons why people seek
healthcare [2]. Among those with lower RTIs, >2.7 million peo-
ple die each year and pneumococcal pneumonia is the cause of
more than half of the deaths [2]. In the current era of avoiding
antibiotic resistance, antibiotic use for treating RTIs should be
minimized. However, antibiotic treatment is advocated for
high-risk groups, such as patients receiving dialysis, when such
patients present with RTIs [3]. Thus it is important to be able to
identify patients at higher risk of mortality from RTIs.
Chronic kidney disease (CKD), characterized as reduced re-
nal function, is a major public health problem affecting 10%
of the global adult population [4]. CKD was defined in 2002 [5]
after the advent of a validated formula in 1999 to measure the
estimated glomerular filtration rate (eGFR) [6]. Increased risk
of death from RTIs in the dialysis population is already well
established [7–9]. The first mortality prediction score in RTI
included renal disease in 1997, but this preceded the currently
used definition of CKD and only identified people with very
severe kidney dysfunction or on dialysis [10]. In recent years,
accumulated evidence has suggested that an increased risk of
RTI-related death extends to patients with non-dialysis-
dependent CKD [11, 12]. However, results are not consistent
[11–15]: the magnitude of this association varies depending on
different settings abnd types of RTIs, and even disappeared in
some studies [14, 15]. Although a number of systematic
reviews have explored the association between CKD and all-
cause mortality or cardiovascular mortality [16–18], none have
focused on infection-related mortality.
To date, it is unknown if pre-existing CKD helps stratify the
risk of death, as RTIs are associated with high mortality risk
related to the acute infection. Current admission scores in the
guideline do not include CKD in the predictor [3] and only
include symptoms such as respiratory rate. If an association be-
tween pre-existing CKD (not on dialysis) and the risk of death
exists in the context of RTIs, then it has important implications
for clinical care in terms of prompt antibiotic treatment and
referring patients for further admission, pointing to infection
prevention for reducing mortality in this population. Here we
performed a systematic review to explore the impact of non-
dialysis-dependent CKD on mortality among people who pre-
sent with RTIs.
MATERIALS AND METHODS
The methods were pre-specified in a protocol that was regis-
tered with PROSPERO, an international prospective register of
systematic reviews (https://www.crd.york.ac.uk/prospero/dis
play_record.php? RecordID¼119599).
Our systematic review was conducted in accordance with
the Preferred Reporting Items for Systematic Reviews and Meta-
analyses guidelines [19].
Search strategy
We performed a systematic literature search to identify all stud-
ies exploring kidney function and mortality in patients with
RTIs. Our search strategy included the relevant key terms: ‘re-
spiratory tract infection’, ‘kidney disease’, ‘creatinine’, ‘glomer-
ular filtration rate’ and ‘mortality’ or ‘acute kidney injury’
(Supplementary data, Item 1). The search was conducted by two
independent researchers (G.S. and X.Q.) using the Cochrane
Central Register of Controlled Trials (CENTRAL, through April
2019), PubMed (1946–April 2019) and Embase (Elsevier; 1974–
April 2019).
Inclusion and exclusion criteria
Studies were included if they met the following criteria: cohort
or case–control studies; adult (18 years of age) with available
kidney function measurements (creatinine, cystatin C or eGFR)
with or without acute kidney injury (AKI); RTIs, such as pneu-
monia and influenza; and mortality, including all-cause mortal-
ity and cause-specific mortality. We excluded case reports, case
series, editorials and review articles. We excluded those with
chronic dialysis or kidney transplantation. There was no restric-
tion of publication year. There was no restriction of gender and
duration of follow-up time. We only included studies in English,
Chinese or Japanese. In the case of multiple publications cover-
ing the same study population, we only included the report
with the longest follow-up.
Exposure
We accepted a wide range of definitions of kidney disease, in-
cluding medical diagnosis of kidney disease, reduced eGFR or
creatinine clearance, elevated serum creatinine, proteinuria,
micro-albuminuria or macro-albuminuria and renal structural
abnormalities.
Outcomes
The primary outcome of interest was all-cause mortality within
studies with a defined duration of follow-up period. The sec-
ondary outcomes included the risk of in-hospital mortality and
30- and 90-day mortality from infection during the study
periods.
Study selection and data extraction
All the systematic search records from different databases were
imported in EndNote (Clarivate Analytics, Philadelphia, PA,
USA). After deduplication, eligible studies were listed and
assessed independently by two reviewers (G.B.S. and M.I.) using
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predefined inclusion criteria. First, we excluded studies based
on their titles and abstracts. Second, we excluded studies based
on the detailed inclusion criteria.
Four authors (G.B.S., M.I., X.D.Q. and H.M.) used predefined
forms to extract data from the studies, including information
on region, study design, participants, definition of infection,
definition of kidney function, definition of mortality, covariates,
results and follow-up period. For each study, relative risk (RR)
including odds ratios (ORs), hazard ratios and incidence rate ra-
tio were extracted (if reported) as well as the ones based on the
most fully adjusted models. If different level groups (e.g. tertiles
of renal function) were reported, then the most extreme com-
parison, that is, lowest versus highest level, was considered for
the primary results. If the RR was not available in the studies,
then the number or incidence of the outcomes was extracted to
calculate the RRs.
Quality assessment
Two review authors (H.M. and M.I.) independently assessed the
risk of bias of each included study using a pre-specified tool
adapted from the Cochrane Collaboration’s tool for observa-
tional studies [20] (Supplementary data, Item 2). Studies were
assigned a high, moderate, low or uncertain risk of each of the
following: selection bias, non-differential measurement error
for exposure and outcome, information bias in exposure and
outcome and confounding. In the case of any disagreement, the
third author (D.N.) also assessed the study.
Statistical analyses
For each outcome measure of interest, random effects meta-
analyses were conducted to pool RRs for mortality to determine
the effect of the presence or absence of kidney disease or level
of renal function.
Hazard ratios and RRs were considered interchangeably in
analyses. If studies only reported ORs, then these were con-
verted into RRs using the formula RR¼OR/[(1  P0)þ (P0OR)],
in which P0 is the event incidence in the control group [21].
A sensitivity analysis was performed to exclude the studies
with this transformation.
The I2 statistic was used to measure heterogeneity across
studies. Heterogeneity was explored through subgroup analyses
whereby results were stratified by different settings of kidney
function measurements [inpatients, intensive care unit (ICU)
and others], time of kidney disease assessment (prior to RTI, on
admission). Additional empirical Bayes meta-regression models
were performed. These included study sample size (<500 versus
500 participants), the timing of kidney disease assessment (on
admission versus prior to pneumonia), types of settings (ICU
versus inpatients) and types of infection (healthcare-associated
versus community-acquired).
Publication bias was assessed by funnel plot and the Begg
test. Forest plots were used to display the mean difference or RR
and 95% confidence interval (CI) for each study and the pooled
summary effect. All data analyses were performed using Stata
15.0 (StataCorp, College Station, TX, USA).
RESULTS
Study selection
We identified 5361 records from systematic searching and 1 re-
cord from reference checking of the key papers. Of these, 4043
records underwent title and abstract screening after removing
duplicates. After excluding 3895 records based on title and ab-
stract screening, 148 records remained for full-text assessment.
We excluded 130 articles that did not meet inclusion criteria
[abstract or no full text available (n¼ 22); included patients with
end-stage renal disease (n¼ 4); language not English, Japanese
or Chinese (n¼ 12); no data of acute RTIs (n¼ 20); no data on
CKD or AKI (n¼ 20); no baseline kidney function data (n¼ 28); no
data on mortality from RTI (n¼ 5); no data of CKD or AKI on
mortality (n¼ 15) and tuberculosis (n¼ 4)]. Eighteen studies met
the eligibility criteria and were considered for meta-analysis
[12–15, 22–34] (Figure 1).
Study characteristics
The studies selected for evaluation enrolled a total of 16 676
participants (Table 1). The studies were from France (n¼ 4) [13,
22, 23, 26], Spain (n¼ 4) [24, 30, 32, 33], China (n¼ 3) [15, 28, 34],
USA (n¼ 3) [14, 25, 27], Mexico (n¼ 1) [31], UK (n¼ 1) [12], Canada
(n¼ 1) [11] and Qatar (n¼ 1) [29]. All were cohort studies except
for one case–control study [31]. Intensive care was the most
common study setting, followed by inpatients, emergency [33],
community [11, 12] and nursing home [32]. The average age
ranged from 29 to 69 years and the proportion of men ranged
from 38% to 78%. Most studies ended follow-up at hospital
discharge.
Fourteen studies, enrolling 16 159 patients, provided data on
pneumonia and the remaining three studies [14, 29, 31], enroll-
ing 517 patients, investigated influenza. Most of the RTI diagno-
ses were either from clinical diagnosis or from International
Classification of Disease codes. Most of the RTIs were
community acquired. Two studies [24, 28] reported that the RTIs
were healthcare-associated and one [15] did not distinguish the
onset of RTIs. There were various definitions of kidney disease,
including the previous history of kidney disease [13, 14, 27, 30,
32], elevated serum creatinine or blood urea nitrogen (BUN) [22–
26, 28, 29, 31, 34] and reduced eGFR [11, 12, 15]. Ten studies [11,
22–26, 28, 29, 31, 34] identified kidney disease prior to the onset
of RTIs and the remaining eight studies reported kidney disease
status on admission. All studies reported short-term all-cause
mortality following a pneumonia diagnosis. Ten studies [13–15,
22–25, 27, 29, 31] reported inhospital mortality and the remain-
ing eight studies reported 28–30 days mortality. One study [12]
reported 90 days mortality.
Risk of bias assessment
The full quality assessment is reported in the Supplementary
data, Table S1. Study quality was variable. Relying on routine
medical history introduced a potential source of misclassifica-
tion of kidney disease status for five studies [13, 14, 27,
30, 32].
Ten studies [13–15, 22–25, 27, 29, 31] reported in-hospital
mortality with an unclear length of hospital stay, making the
duration of follow-up unclear. All included studies identified
deaths from death registers or hospital records extraction, with
a low risk of misclassification of mortality. There was variable
adjustment for confounding, from unadjusted crude estimates
to estimates adjusted for a range of comorbidities and
demographics.
The effect of kidney disease on mortality in patients
with RTIs
When compared with individuals without kidney disease, the
pooled adjusted risk for all-cause mortality in patients with
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RTIs almost doubled [RR 1.96 (95% CI 1.48–2.59)] in those with
kidney disease and with high heterogeneity (I2¼ 86.2%, P< 0.01;
Figure 2).
The effect of kidney disease on mortality in patients
with influenza
In patients with influenza, the presence of kidney disease was
associated with increased mortality risk. However, it did not
reach conventional levels of statistical significance [RR 1.54
(95% CI 0.62–3.81)] due to low power and moderate heterogene-
ity (I2¼ 2.5%, P¼ 0.12; Supplementary data, Figure S1).
The effect of kidney disease on mortality in patients
with pneumonia
In patients with pneumonia, the all-cause mortality was more
than two times higher [RR 2.02 (95% CI 1.51–2.72)] with high het-
erogeneity (I2¼ 87.8%, P< 0.01; Figure 2). Higher risk of all-cause
mortality in patients with pneumonia was observed in those
with kidney disease, regardless of the timing of kidney disease
measurement (prior to RTIs or on admission, Supplementary
data, Figure S2) or setting (ICU, inpatients and others; Figure 2).
The results were consistent in those with community-acquired
pneumonia (CAP), healthcare-associated pneumonia
(Supplementary data, Figure S3) and in-hospital or 28-/30-day
CKD 
Records idenfied through databases        
Pubmed (1946 to April 2019): 431 
CENTRAL (Till April 2019): 729  
EMBASE (Elsevier) (1974 to April 2019): 1723  
 (n=2,883) 
Records from other source (n=1) 
Records aer duplicates removed 
 (n= 2452) 
AKI 
Records idenfied through English databases        
Pubmed (1946 to April 2019): 393 
CENTRAL (Till April 2019): 302 
EMBASE (Elsevier) (1974 to April 2019): 1783 
 (n=2478) 
Records from other source (n=0) 
Records aer duplicates removed 
 (n= 2087) 
Records (n = 4,539) 
Records excluded  
(n = 3,895) 
Full-text arcles assessed for eligibility 
(n = 148 )
Full-text arcles excluded, with reasons 
(n = 130) 
Abstract or no full text available (n=22)
Included paents with End-stage renal 
disease (n=4) 
Language not English, Japanese or 
Chinese (n= 12) 
No data of acute respiratory tract 
infecons (n= 20) 
No data of CKD or AKI (n=20) 
No baseline kidney funcon on mortality 
(n=28) 
No data on mortality from respiratory 
tract infecon (n= 5) 
No data of CKD or AKI on mortality 
(n=15) 
Tuberculosis (n=4) 
Title and abstracts screened  
(n = 4,043)
Duplicates records 
excluded (n = 496) 
Records for analysis 
(n = 18) 
FIGURE 1: Flow chart. AKI: acute kidney injury; CKD: chronic kidney disease.
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mortality (Supplementary data, Figure S4). Only one included
study reported the risk of 90-day mortality as 27% higher in
those with reduced eGFR than those with eGFR >60 mL/min/
1.73 m2 [RR 1.27 (95% CI 1.12–1.43)] [12].
Meta-regression and sensitivity analyses
A sensitivity analysis restricted to the 11 studies without OR
transformation demonstrated a similar association between the
presence of kidney disease and a higher risk of all-cause mortal-
ity (Supplementary data, Figure S5).
Meta-regression analyses suggested that the RRs were
higher for larger studies compared with smaller studies, inpa-
tient settings compared with intensive care settings, kidney dis-
ease assessed prior to hospitalization compared with on
admission and healthcare-associated pneumonia compared
with community-acquired, although CIs included the null
(Table 2).
Publication bias
Publication bias was not evident from the funnel plot of in-
cluded studies (P¼ 0.46 in the Begg’s test, Supplementary data,
Figure S6).
DISCUSSION
This meta-analysis, based on 18 studies of patients with RTIs,
showed that the risk of all-cause death was increased, with a
high heterogeneity between studies that was explained by
study size, setting, type of RTI and timing of assessment of kid-
ney disease status. Overall, the risk of mortality was
FIGURE 2: Forest plot depicting the meta-association between the presence of kidney disease and the risk of death in patients with RTIs in different settings.
Table 2. Meta-regression analyses on association between the presence of kidney disease and the risk of death in patients with pneumonia




meta-regression pooled RR (95% CI) P-value I2 (%)
All-cause mortality
Community-acquired versus healthcare-associated 14 0.82 (0.39–1.69) 0.55 88
Kidney disease assessment prior to pneumonia versus on admission 15 0.92 (0.55–1.55) 0.75 88.6
Inpatients versus ICU 11 1.16 (0.70–1.91) 0.53 49.3
Number of participants 500 versus <500 14 0.75 (0.46–1.23) 0.23 89.9
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approximately two times higher in patients with kidney disease
and pronounced in patients with pneumonia.
Our observations are in line with the evidence from previous
studies. In the community setting, James et al. [11] and
McDonald et al. [12] observed a graded association between re-
duced eGFR and a higher risk of 30-day mortality in patients
hospitalized for pneumonia. This association was consistent in
the meta-analysis irrespective of the context, even though the
underlying illness usually drives the high risk of mortality. In
line with the severity of the underlying RTI, the predicting mor-
tality value of kidney disease was more pronounced in the
patients presenting in the community and in inpatients when
compared with the ICU setting. Similarly, assessment of kidney
disease prior to infection was a stronger predictor than kidney
function assessed on admission. Many clinical prediction tools
for CAP have included BUN as an indicator of kidney disease, in-
cluding the Pneumonia Severity Index [10], CURB-65 [Confusion,
Urea >7 mmol/l, Respiratory rate 30/min, low systolic
(<90 mm Hg) or diastolic (60 mm Hg) Blood pressure), age 65
years] [35] and minor criteria from the Infectious Diseases
Society of America/American Thoracic Society guidelines [36].
These tools have been validated to identify high-risk patients
and their implementation can improve patients’ outcomes [37,
38]. Our results suggest that pre-existing general practitioner
health records can also inform whether to treat or to admit
patients who have had previous creatinine measurements [11,
12]. These findings highlight the importance of ascertaining the
type of pre-existing kidney disease and not just acute increases
in urea as a result of dehydration when patients present with
RTIs, especially in the community setting.
Most included studies defined kidney disease by using re-
duced eGFR or medical history. Fewer studies have examined
albuminuria. A study by McDonald et al. [12] in the UK reported
a non-significant association of proteinuria with mortality in
patients with pneumonia. Meanwhile, in the Atherosclerosis
Risk in Communities study, Ishigami et al. [39] observed a strong
dose–response association between the urinary albumin:creatinine
ratio (ACR) and the risk of death from hospitalization with infec-
tions. This association was independent of eGFR. Indeed, when
assessed in the context of CKD risk stage according to the
Kidney Disease: Improving Global Outcomes [40], there were
multiplicative contributions of low eGFR and high ACR to mor-
tality. The role of ACR in the risk of death in patients with RTIs
requires more studies for confirmation.
Several factors might contribute to the higher all-cause mor-
tality in patients with kidney disease in the context of RTIs. One
of the links might be cardiovascular disease (CVD). Patients
with CKD may have higher CVD mortality associated with RTIs,
eventually contributing to higher all-cause mortality. It is well
known that patients with CKD have a higher risk of CVD [16, 41].
Previous studies also showed that an episode of infection
increases CVD mortality and this association was more pro-
nounced in those with reduced renal function [42, 43]. The oc-
currence of CVD complications in patients with RTIs has been
associated with increased short- and long-term mortality [44,
45]. The underlying mechanism is multifactorial and likely to
include exacerbation of systemic inflammatory changes in ath-
erosclerotic plaques inducing demand ischaemia, thereby lead-
ing to an increased risk of death from CVD [45–47]. Kidney
disease is already associated with increased malnutrition, ele-
vated serum inflammatory cytokines levels and oxidative stress
[48, 49]. The inflammatory storm from RTIs may be more in-
tense in patients with kidney disease. Another link might be re-
lated to AKI. Patients with kidney disease are prone to AKI,
which is a well-established independent factor for CVD and
death [50].
For policymakers, the results of this systematic review high-
light the importance of underlying kidney disease for patients
with pneumonia, which should be considered in clinical quality
indicators and incentivization as well as public health policy,
such as immunization drives. For clinicians, our results confirm
the importance of checking pre-existing kidney disease comor-
bidities in patients seeking medical care for symptoms of RTIs.
For guideline developers, pre-existing kidney disease might also
be considered for inclusion in hospital admission scores [3]. For
patients with CKD, pneumonia carries a higher risk of death,
and pneumococcal and influenza vaccination should be encour-
aged as one of the prevention strategies. It is concerning that
patients with CKD have lower and shorter protective effects
from vaccination, because many people with CKD often do not
receive pneumococcal vaccination and their immunity wanes
over time [51, 52].
Our study has several strengths. We performed a sensitive
and comprehensive search strategy, with a broad definition of
kidney disease, for a thorough and inclusive search. We were
able to show that the presence of kidney disease, whether
assessed prior to infection or measured on admission, was
associated with a higher risk of mortality in patient with pneu-
monia. This association was consistent in different settings
and for both community-acquired and healthcare-associated
infections.
We also acknowledge the limitations that need to be consid-
ered when interpreting our findings. First, most of the included
studies in our systematic review only reported all-cause in-hos-
pital mortality or 28-/30-day mortality, and we were unable to
investigate long-term mortality and cause-specific mortality.
Second, most of the included studies used the measurements of
kidney function at admission, which might reflect pre-existing
kidney function or AKI. However, subgroup analysis showed a
consistent association between pre-existing kidney disease
(prior to infections) and higher risk of death in those with pneu-
monia. Third, our analysis plan selected the most adjusted RR
presented in the included studies (as representing the least con-
founded and therefore most conservative risk estimation),
which may have resulted in outcome reporting bias. Fourth, as
our meta-analysis was based on observational studies, residual
or unmeasured confounding could not be eliminated. Fifth,
we found overall high heterogeneity in our estimates.
Heterogeneity may be attributed in part to the differences in pa-
tient characteristics (e.g. sex distribution, mean age and comor-
bidities such as diabetes), definition of kidney disease (medical
history, eGFR, etc.) and different onset of RTIs, follow-up peri-
ods, study quality and sample sizes. However, we were unable
to perform all these subgroup analyses owing to the limited
data available and lack of access to the original, individual pa-
tient data. Sixth, it should be noted that only one study included
pneumonia managed in the community [12], and this was lim-
ited to a study population of older adults with diabetes, thus
caution is needed in applying these findings outside hospital
settings. Seventh, we cannot exclude publication bias for some
small studies included in this review, although most studies are
large and results appear robust.
In conclusion, the presence of kidney disease is associated
with a higher risk of death in patients with RTIs, especially in
those with pneumonia. Clinicians should not only use the pres-
ence of kidney disease as an indication to start antibiotic ther-
apy for RTI but also, in view of their higher mortality risk,
consider that these patients may require hospital admission.
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